Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Adagene Inc ADAG

Healthcare Biotechnology
Adagene Inc is a platform-driven, clinical-stage biopharmaceutical company committed to transforming the discovery and development of novel antibody-based cancer immunotherapies. The Company is principally engaged in the research, development and production of monoclonal antibody drugs for cancers. The Company’s main products include: ADG106 is being developed for the treatment of advanced... see more

Recent & Breaking News (NDAQ:ADAG)

Adagene Presents Preclinical Data Showcasing Best-in-Class Profiles for ADG153, an Anti-CD47 SAFEbody® and ADG152, a CD20xCD3 Bispecific T-cell Engager POWERbody(TM)

GlobeNewswire December 13, 2021

Adagene Presents Clinical Data Demonstrating Strong Safety and Early Signals of Efficacy in Cold Tumors Including Pancreatic and Ovarian Cancers for Anti-CTLA-4 Monoclonal Antibody, ADG116, at ESMO-IO 2021

GlobeNewswire December 6, 2021

Adagene Presents Clinical Data Demonstrating Strong Safety and Early Signals of Efficacy in Treatment-Resistant Tumors for Anti-CTLA-4 Monoclonal Antibody, ADG116, at ESMO-IO 2021

GlobeNewswire December 6, 2021

Adagene Announces FDA Clearance of IND for Phase 1b/2 Trial of Anti-CTLA-4 Monoclonal Antibody ADG116 in Combination Therapy with Anti-PD-1 Antibody Pembrolizumab

GlobeNewswire November 29, 2021

Adagene Announces Poster Presentations of Clinical Data for Two Novel Antibody Programs at ESMO Immuno-Oncology Congress 2021

GlobeNewswire November 22, 2021

Adagene to Participate in Upcoming Investor & Industry Conferences in November

GlobeNewswire November 9, 2021

Adagene Unveils Preclinical Data from Two Transformative Antibody Programs at Upcoming American Society of Hematology (ASH) Annual Meeting

GlobeNewswire November 4, 2021

Adagene Establishes Collaboration for Clinical Trial of ADG106 in Combination with Nivolumab in Patients with Non-Small Cell Lung Cancer in Singapore

GlobeNewswire October 27, 2021

Adagene to Participate in the Jefferies Virtual China Biotech Summit

GlobeNewswire October 21, 2021

Adagene to Participate at the Morgan Stanley 19th Annual Global Healthcare Conference

GlobeNewswire September 2, 2021

Adagene Reports Financial Results for the Six Months Ended June 30, 2021 and Provides Corporate Updates

GlobeNewswire August 26, 2021

Adagene Announces the Third Clinical Trial Collaboration with Merck to Advance Anti-CD137 Agonist, ADG106, in Combination Therapy with KEYTRUDA® (pembrolizumab)

GlobeNewswire August 19, 2021

Adagene Announces Appointment of Interim Chief Medical Officer and New Members of Scientific and Strategic Advisory Board

GlobeNewswire August 12, 2021

Adagene Announces Clinical Trial Collaboration With Merck to Advance Two Anti-CTLA-4 Monoclonal Antibody Programs (ADG116 and ADG126) in Combination Therapy with KEYTRUDA® (pembrolizumab)

GlobeNewswire July 22, 2021

Adagene Announces Authorization of Share Repurchase Program up to US$20 Million

GlobeNewswire July 7, 2021

Adagene Announces Inclusion in FTSE Russell Indexes

GlobeNewswire June 16, 2021

Adagene to Present at Upcoming Investor Conferences

GlobeNewswire May 25, 2021

Adagene Presents Clinical Data from NEObody(TM) Program, ADG106, Anti-CD137 Agonist, in an Abstract at ASCO 2021 Annual Meeting

GlobeNewswire May 19, 2021

Adagene Reports Full Year 2020 Financial Results and Provides Corporate Updates

GlobeNewswire March 31, 2021

Adagene Announces Clinical Advancement for ADG116

GlobeNewswire March 29, 2021